Adenosine triphosphate

Drug Profile

Adenosine triphosphate

Latest Information Update: 25 May 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Adenine nucleotides; Antiarrhythmics; Infertility therapies; Small molecules
  • Mechanism of Action Nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cachexia
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 25 May 2001 Profile reviewed but no significant changes made
  • 02 Dec 1998 No-Development-Reported for Cachexia in USA (Unknown route)
  • 28 Aug 1998 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top